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Abstract
The total synthesis of (+)-iriciniastatin A (psymberin) is reported in 19 steps and 6% overall yield.
Key reactions include a highly convergent enolsilane-oxocarbenium ion union to generate the C8-
C25 fragment and a late stage coupling of a hemiaminal and acid chloride to complete the synthesis.
In 2004, Pettit and Crews independently reported the isolation of two remarkably potent and
selective cancer cell growth inhibitors from the extracts of deep water sponges. Irciniastatin A
(1) was obtained from Ircinia ramosa by Pettit,1 and psymberin from Psammocina sp. by
Crews.2 The two secondary metabolites were shown to be structurally related based on
spectroscopic studies, however, incomplete and conflicting stereochemical analyses precluded
a definitive assignment of absolute configuration. Each displayed incredibly powerful and
selective cancer cell growth inhibition. Irciniastatin A was reported to exhibit a greater than
104 differential in activity across related cell lines. The limited natural abundance and lack of
an absolute stereochemical assignment, as well as interest in further exploration of the unique
chemotherapeutic profile and mode of action, sparked immediate interest within the synthetic
community.
Early reports shed light on the stereochemical ambiguities through fragment synthesis3 and
natural product degradation.4 Ultimately, it was the seminal total synthesis by DeBrabander5
that confirmed the absolute configuration and demonstrated that irciniastatin A (1) and
psymberin were identical. Subsequent reports, including fragment synthesis,6 a formal
synthesis,7 two total syntheses,8,9 and two reports of analog syntheses,10,11 all offered creative
and distinct approaches toward the unique structural elements of irciniastatin A.
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Our interest in (+)-irciniastatin A (psymberin) focused on developing a highly
diastereoselective and modular synthesis that might be suitable for analog preparation. Our
efforts toward (+)-1, recently culminated in a completed total synthesis which is reported here.
Retrosynthetically (Scheme 1), (+)-irciniastatin A (1) was envisioned to arise from two key
disconnections. A late stage attachment of the psymberic acid chain would be accomplished
by coupling of acid chloride 2 with hemiaminal 3, the product of a Curtius rearrangement of
the carboxylic acid derived from benzyl ether 4. This tactic would allow for a highly
stereocontrolled entry to the C8 hemiaminal and efficient incorporation of the side chain.
Tetrahydropyran 4 would arise from the stereoselective addition of enolsilane 6 to the
oxocarbenium-ion derived from acetate 5. These two key disconnections segregate the three
major subunits of irciniastatin A (1); each of similar size and complexity and accessible in a
highly stereocontrolled fashion from standard aldol synthons.
All reported syntheses of the psymberate side chain have relied on functionalizing
commercially available chiral pools or enzymatic resolutions. In addition, analog studies10,
11 have shown the side chain to be required for high activity. Therefore, an enantioselective
and highly tunable synthesis of the side chain would be ideal for further investigation of side
chain function. We reasoned that an oxazolidinethione asymmetric glycolate aldol reaction12
would allow for enantioselective entry to the psymberate side chain as well as provide sufficient
opportunities for derivitization and congener synthesis. The synthesis of acid chloride 2
(Scheme 2) began with the known13 anti-aldol12a reaction of glycolate 9 and 3-methyl-but-3-
enal to deliver aldol adduct 10 that was converted to known TIPS ether 11.13 Methylation of
the alcohol was followed by removal of the allyl protecting group under Kulinkovich
conditions13,14 to give alcohol 12. Protection of alcohol 12 as the SEM ether was followed by
selective removal of the primary TIPS ether. The resultant primary alcohol 13 was oxidized
under Smith's conditions giving the corresponding acid over two steps. The acid (9 steps, 28%
overall) was converted to acid chloride 2.
The synthesis of the acetate 5 (Scheme 3) began from known p-methoxybenzylidine acetal
1415 available from 2-deoxy-D-ribose in two steps. Methylation of alcohol 14 was followed
by a dihydroxylation-oxidative cleavage sequence to reveal aldehyde 16. A catalyst controlled
Kiyooka16 aldol reaction of aldehyde 16 and enolsilane 1717 provided carbinol 18 in 84% yield
and 9:1 dr. Protection of alcohol 18 to give TBS ether 19 was followed by acid-catalyzed
cyclization to provide a 10:1 mixture of lactone 20 and the corresponding diol, which was
converted to lactone 20 by exposure to CF3CO2H. Protection of the primary alcohol gave
benzyl ether 21 and subsequent one-pot reductive acetylation18 afforded acetate 5 in
quantitative yield (9 steps, 34% overall from 2-deoxy-D-ribose).
The synthesis of enolsilane 6 (Scheme 4) began from known catechol 246,19 prepared by
cycloaddition of allene 2320 and diene 22.21 Protection of catechol 24 as the bis-TIPS ether
was followed by selective ester reduction to give aldehyde 25 in 78% yield over 2 steps. An
asymmetric propionate aldol22 reaction of aldehyde 25 and propionyl thiazolidinethione 26
afforded the Evans-syn-aldol adduct 27 in 94% yield and >20:1 dr. Direct displacement of the
chiral auxiliary with Weinreb's amine was followed by protection of the secondary alcohol as
a TBS ether to deliver silyl ether 28. The methyl ketone prepared from Weinreb's amide 28,
was then readily converted to desired enolsilane 6 (7 steps; 66% overall from catechol 24).
Having devised highly stereocontrolled routes to all three key fragments, the union of
enolsilane 6 and acetate 5, was investigated (Scheme 5). Rigorous experimentation revealed
that BF3●OEt2 was the optimum Lewis acid and that TBS enolsilane 6 performed better than
the corresponding TMS enolsilane for the assembly of 5 and 6. Most intriguing, however, was
that addition of a solution of enolsilane 6 to a premixed solution of 5 and BF3●OEt2 at -40 °C
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was required for efficient coupling. The union proceeded with high diastereoselectivity, giving
tetrahydropyran 4 as the only detectable diastereomer. The high diastereoselectivity can be
rationalized by well precedented23 pseudoaxial addition of the nucleophile to the
oxocarbenium conformer 29, proceeding through a favorable chair-like conformation.
Conformer 29 would also be expected to be favored as a result of through-space stereoelectronic
stabilization23 of the oxocarbenium ion by the axially positioned C11 ether.
With the C8-C25 carbon framework in place, conditions to set the C15 stereocenter were
investigated (Scheme 6). Standard achiral reducing agents proved to be non-selective or
completely selective for the undesired diasteromer,24 however, the use of the chiral (R)-
CBS25 agent exclusively provided desired diastereomer 3026 in 82% yield. After protection of
the secondary alcohol as its TBS ether and cleavage of the benzyl ether, carbinol 31 was
oxidized over 2 steps to carboxylic acid 32. Initial studies showed the one-pot Curtius reaction
with (O,O)-diphenylphosphoryl azide27 to be ineffective, providing significant quantities of
inseparable carbamoyl azide impurity.28 Therefore, Weinstock's procedure9,29 was employed
to generate the intermediate isocyanate, which under mild conditions using copper (I) chloride
afforded Teoc-protected hemiaminal 33.30 Much to our dismay, a screen of reported
conditions31 for acylation of stucturally related intermediates never yielded N-acyl hemiaminal
34. A survey of the previous syntheses of irciniastatin A finds that all feature a late stage aminal
and side chain incorporation with a preformed lactone of the dihydroisocoumarin. Albeit
unlikely that such remote functionality should have any effect on the hemiaminal coupling, the
limited number of available options warranted pursuit of this lead.32
Strategically, after the CBS reduction, the lactone was formed concomitantly with removal of
the TBS ether to give 35 adding only one synthetic step over the original plan (bottom of
Scheme 6). An analogous sequence of TBS protection of the C15 carbinol and hydrogenolysis
of the benzyl ether gave carbinol 36, which was subjected to a two step oxidation to acid 37.
Acid 37 was subjected to the previously established Curtius conditions to give hemiaminal 3.
With hemiaminal 3 featuring the lactonized dihydroisocoumarin, it was found that i-PrMgCl,
a base not previously used for this transformation, successfully effected reaction with acid
chloride 2 in a remarkable 87% yield. Finally, global deprotection with TASF in DMF at 50 °
C provided (+)-irciniastatin A (1) in 94% yield.
In summary, the total synthesis of (+)-irciniastatin A (1) was completed in 19 steps with a 6%
overall yield from 2-deoxy-D-ribose. The successful application of this strategy allowed for
rapid assembly of the three key fragments with high diastereocontrol. Studies directed toward
analog synthesis and further evaluation of the antitumor activity of irciniastatn A are underway
in collaboration with the Lineberger Comprehensive Cancer Center.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
Financial support from the National Institute of General Medical Sciences (GM60567) is gratefully acknowledged.
References
1. Pettit GR, Xu JP, Chapuis JC, Pettit RK, Tackett LP, Doubek DL, Hooper JNA, Schmidt JM. J Med
Chem 2004;47:1149. [PubMed: 14971894]
2. Cichewicz RH, Valeriote FA, Crews P. Org Lett 2004;6:1951. [PubMed: 15176791]
3. Kiren S, Williams LJ. Org Lett 2005;7:2905. [PubMed: 15987166]
Crimmins et al. Page 3













4. Green ME, Rech JC, Floreancig PE. Org Lett 2005;7:4117. [PubMed: 16146366]
5. Jiang X, Garcia-Fortanet J, DeBrabander JK. J Am Chem Soc 2005;127:11254. [PubMed: 16089449]
6. (a)Rech JC, Floreancig PE. Org Lett 2005;7:5175. [PubMed: 16268531](b)Henssen B, Kasparyan E,
Marten G, Pietruszka J. Heterocycles 2007;74:245.(c)Pietruszka J, Simon R. Eur J Org Chem
2009:3628. The following report appeared during the preparation of this manuscript:(d)Brown LE,
Landaverry YR, Davies JR, Milinkevich KA, Ast S, Carlson JS, Oliver AG, Konopelski JP. J Org
Chem. 2009 ASAP
7. Shangguan N, Kiren S, Williams LJ. Org Lett 2007;9:1093. [PubMed: 17319675]
8. Huang X, Shao N, Palani A, Aslanian R, Buevich A. Org Lett 2007;9:2597. [PubMed: 17523653]
9. Smith AB III, Jurica JA, Walsh SP. Org Lett 2008;10:5625. [PubMed: 19072197]
10. (a) Huang X, Shao N, Huryk R, Palani A, Aslanian R, Seidel-Dugan C. Org Lett 2009;11:867.
[PubMed: 19199777] (b) Huang X, Shao N, Palani A, Aslanian R, Buevich A, Seidel-Dugan C,
Huryk R. Tetrahedron Lett 2008;49:3592.
11. Jiang X, Williams N, De Brabander JK. Org Lett 2007;9:227. [PubMed: 17217271]
12. (a) Crimmins MT, McDougall PJ. Org Lett 2003;5:591. [PubMed: 12583777] (b) Crimmins MT, She
J. Synlett 2004:1371.
13. Crimmins MT, McDougall PJ, Emmitte KA. Org Lett 2005;7:4033. [PubMed: 16119960]
14. Lee J, Cha JK. Tetrahedron Lett 1996;37:3663.
15. (a) Fürstner A, Schlede M. Adv Synth Catal 2002;344:657. (b) Uehara H, Oishi T, Inoue M, Shoji
M, Nagumo Y, Kosaka M, Le Brazidec JY, Hirama M. Tetrahedron 2002;58:6493.
16. Kiyooka SI, Kira H, Hena MA. Tetrahedron Lett 1996;37:2597.
17. Juaristi E, Cruz-Sanchez S. J Org Chem 1988;53:3334.
18. (a) Kopecky DJ, Rychnovsky SD. J Org Chem 2000;65:191. [PubMed: 10813915] (b) Dahanukar
VH, Rychnovsky SD. J Org Chem 1996;61:8317. [PubMed: 11667826]
19. Langer P, Kracke B. Tetrahedron Lett 2000;41:4545.
20. (a) Node M, Fujiwara T, Ichihashi S, Nishide K. Tetrahedron Lett 1998;39:6331. (b) Isobe T, Ishikawa
T. J Org Chem 1999;64:6984.
21. Langer P, Schneider T, Stoll M. Chem-Eur J 2000;6:3204.
22. (a) Crimmins MT, King BW, Tabet EA. J Am Chem Soc 1997;119:7883. (b) Crimmins MT,
Chaudhary K. Org Lett 2000;2:775. [PubMed: 10754681] (c) Crimmins MT, King BW, Tabet EA,
Chaudhary K. J Org Chem 2001;65:894. [PubMed: 11430110] (d) Crimmins MT, Shamszad M. Org
Lett 2007;9:149. [PubMed: 17192107]
23. Ayala L, Lucero CG, Romero JAC, Tabacco SA, Woerpel KA. J Am Chem Soc 2003;125:15521.
[PubMed: 14664599]
24. DIBAL in toluene at -78 °C was completely selective for the undesired isomer.
25. Corey EJ, Bakshi RK, Shibata S, Chen CP, Singh VK. J Am Chem Soc 1987;109:7925. For a review
see: Corey EJ, Helal CJ. Angew Chem Int Ed Engl 1998;37:1987.
26. Rychnovsky SD, Rogers B, Yang G. J Org Chem 1993;58:3511.Also see supporting information.
27. Shioiri T, Yamada S, Ninomiya K. J Am Chem Soc 1972;94:6203. [PubMed: 5054412]
28. (a) Shioiri T, Yamada SI. Chem Pharm Bull 1974;22:855. (b) Csuk R, Schabel MJ, von Scholz YV.
Tetrahedron: Asymmetry 1996;7:3505. (c) Sibi MP, Lu J, Edwards J. J Org Chem 1997;62:5864.
29. Weinstock J. J Org Chem 1961;26:3511. Also see: Smith AB III, Safonov IG, Corbett RM. J Am
Chem Soc 2002;124:11102. [PubMed: 12224958]
30. (a) Duggan ME, Imagire JS. Synthesis 1989:131. (b) Evans SD, Houghton RP. J Mol Catal
2000;164:157.
31. (a) Jewett JC, Rawal VH. Angew Chem Int Ed Engl 2007;46:6502. [PubMed: 17645272] (b) Marron
TG, Roush WR. Tetrahedron Lett 1995;36:1581. (c) Roush WR, Pfeiffer LA. Org Lett 2000;2:859.
[PubMed: 10754688] (d) Kagawa N, Ihara M, Toyota M. J Org Chem 2006;71:6796. [PubMed:
16930029]
32. NOE experiments on related compounds by DeBrabander indicate a close spatial relationship between
these two regions of the molecule (see reference 11).
Crimmins et al. Page 4














Retrosynthetic Analysis of Irciniastatin A
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Synthesis of the Psymberic Acid Side Chain
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Synthesis of Acetate 5
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Synthesis of Enolsilane 6
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Coupling of Acetate 5 with Enolsilane 6
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Completion of the Synthesis of (+)-Irciniastatin A
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